Ellen Chuang, M.D.
I seek to provide state-of-the art breast cancer care in a small, personalized setting. In this environment, patients are encouraged to learn and to participate in decision making processes.
Dr. Ellen Chuang is an Associate Professor of Clinical Medicine in the Department of Medicine, Division of Hematology and Medical Oncology at New York Presbyterian-Weill Cornell Medical Center.
Dr. Chuang graduated from the Johns Hopkins University and received her medical degree from the University of Chicago. She completed a residency in Internal Medicine from the University of Iowa and a fellowship in Hematology/Oncology at Indiana University School of Medicine. She returned to the University of Chicago to pursue a research fellowship in Immunology. Dr. Chuang joined the faculty of the Weill Cornell Medical College in 1999.
Dr. Chuang specializes in the treatment of breast cancer. Her clinical practice is located at the Weill Cornell Breast Center, where she is fortunate to work with a superb team of breast surgeons, medical oncologists, radiation oncologists, radiologists, and pathologists. Dr. Chuang is an investigator on several clinical trials, and has published and lectured on her work on numerous occasions. She is a member of the the New York Metropolitan Breast Cancer Society, and the American Society of Clinical Oncology. She enjoys her role as a teacher and mentor to medical students, residents, and fellows.
Insurance Plans Accepted
The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please feel free to contact this physician or this physician's practice as they may have individual contracts not included on this site.
- AETNA [HMO]
- AETNA [PPO]
- AETNA [Medicare]
- Aetna - Weill Cornell [POS]
- Affinity Essential
- Affinity Health Plan
- Blue Priority Network
- Emblem Select Care
- Empire Blue Cross/Blue Shield [Pathway X]
- Empire Blue Cross/Blue Shield [Pathway X Enhanced]
- Empire Blue Cross/Blue Shield [PPO]
- Empire Blue Cross/Blue Shield [EPO]
- Empire Blue Cross/Blue Shield [HMO]
- Empire Blue Cross/Blue Shield [Mediblue (Senior)]
- Fidelis Care
- GHI [CBP]
- Health First
- Health Insurance Plan of NY (HIP) [Medicare]
- Health Insurance Plan of NY (HIP) [Medicaid]
- Health Insurance Plan of NY (HIP)
- Health Plus - Amerigroup [CHP]
- Health Plus - Amerigroup
- Health Republic
- Medicare [Medicare]
- Oxford Health Plans [Medicare Advantage]
- Oxford Health Plans [Liberty]
- Oxford Health Plans [Freedom]
- Rockefeller University - CoreSource
- UHC Compass
- United Empire
- United Health Care
- United Health Care [Medicare]
- United Health Care [Community Plan]
- VNSNY CHOICE Medicare [Medicare]
- VNSNY CHOICE Medicare [HMO]
1. Chuang, E., Barnard, D., Hettich, L., Zhang, X, Avruch, J., and Marshall, M.S. Critical Binding and Regulatory Interactions between Ras and Raf Occur through a Small, Stable N-Terminal Domain of Raf and Specific Ras Effector Residues. Mol. and Cell. Bio. Aug. 1994 p. 5318-5324
2. Barnard, D., Diaz, B., Hettich, L., Chuang, E., Zhang, X., Avruch, J., and Marshall, M. S. Identification of the sites of Interaction Between c-RAF-1 and Ras-GTP. Oncogene Apr. 1995 p.1283-90.
3. Alegre, M.-L., Noel, P.J., Eisfelder, B.J., Chuang, E., Clark, M. R., Reiner, S.L, and C.B. Thompson. Regulation of Surface and Intracellular Expression of CTLA4 on Mouse T Cells. J. Immunology, Dec. 1996 p.4762-4770.
4. Chuang, E., Alegre, M.-L, Duckett, C.S., Noel, P.J., Vander Heiden, M.G., and Thompson, C.B. Interaction of CTLA-4 with the Clathrin-Associated Protein AP50 Results in Ligand-Independent Endocytosis that Limits Cell Surface Expression. J. Immunology, July 1997 p.144-151.
5. Lee, K.-M., Chuang, E., Griffin, M., Khattri, R., Hong, D.K., Zhang, W., Straus, D., Samelson, L.E., Thompson, C.B., and Bluestone, J.A. Molecular Basis of T cell Inactivation by CTLA-4. Science, Dec. 1998 p. 2283-2266.
6. Chuang, E., Lee, K.-M., Robbins, M.C., Duerr, J.M., Alegre, M.-L., Hambor, J.E., Neveu, M.J., Bluestone, J.A., and Thompson, C.B. Regulation of CTLA-4 by Src Kinases. J. Immunology, Feb. 1999 p. 1270-1277.
7. Chuang E., Masteller, E.L., Mullen, A.C., Reiner, S.L., and Thompson, C.B. S. Structural Analysis of CTLA-4 Function in Vivo. J. Immunology, May 2000 p. 5319-5327.
8. Chuang, E., Fisher, T.S., Robbins, M.D., Duerr, J.M., Morgan R.W., VanderHeiden, M.G., Gardner J.P., Hambor J.E., Neveu, M.J., and Thompson, C.B. The CD28 and CTLA-4 Receptors Associate with the Serine/Threonine Phosphatase PP2A. Immunity, September 2000 p. 313-322.
9. Parnes, H.L., Cirrincione, C., Aisner, J., Barry, D.A., Allen, S.L., Abrams, J., Chuang, E, Cooper, M.R., Perry, M.C., Duggan, T.P., Strakowski, T.P., Henderson, I.C., and Norton, L. A Phase III Study of CAF versus CAF plus Leucovorin for Metastatic Breast Cancer: CALGB 9140. Journal of Clinical Oncology, May 2003 p. 1819-24.
10. Yi, L.A., Hajialiasgar, H., and Chuang, E. Tyrosine-mediated inhibitory signals contribute to CTLA-4 function in vivo. International Immunology, April 2004 p. 539-47.
11. Kwang W.H., Sweatt, W.B., Mashayekhi, M., Palucki, D.A., Sattar, H., Chuang, E., and Alegre, M.-L. Transgenic Expression of CTLA-4 Controls Lymphoproliferation in IL-2-Deficient Mice. J. Immunology, Nov. 2004 p. 5415-24.
12. Cheung, K., Tam, W., Chuang, E., Osborne, M. Concurrent invasive ductal carcinoma and chronic lymphocytic leukemia manifesting as a collision tumor in breast. Breast J. 2007 Jul-Aug;13(4):413-7.
13. Naik, R.P., Jin, D., Chuang, E. Gold, E.G., Tousimis, E.A., Moore, A.L., Christos, P.J., deDalmas, T., Donovan, D., Rafii, S. and Vahdat, L.T. Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer. Breast Cancer Research and Treatment. 2008 Jan;107(1):133-8.
14. Vahdat, L.T., Pruitt, B., Fabian, C.J., Rivera, R.R., Smith, D.A., Tan-Chiu, E., Wright, J., Tan, A.R., DaCosta, N.A., Chuang, E., Shuster, D.E., Meneses, N.L., Chandrawansa, K., Fang, F., Cole, P.E., Ashworth, S., and Blum, J.L. A phase II study of eribulin mesylate (E7389), a halichondrin b analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology, 2009 Jun 20;27(18):2954-61.
15. Kozloff, M., Chuang, E., Starr, A. Gowland, P., Cataruozolo, P., Collier, M. , Verkh, L., Huang, X., Kern, K. Miller, K. D. An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer. Ann Oncol. 2009 Dec 23.
16. Chuang, E. Wiener, N., Christos, P., Kessler, R., Cobham, M., Donovan, D., Goldberg, GL, Caputo, T, Doyle, A. Vahdat, L., Sparano, JA. Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary. Ann Oncology 2010 Mar 3.
17. Blinder V.S., Murphy M.M., Vahdat L.T., Gold H.T., de Melo-Martin I., Hayes M.K., Scheff R.J., Chuang E., Moore A., Mazumdar M. Employment After a Breast Cancer Diagnosis: A Qualitative Study of Ethnically Diverse Urban Women. J Community Health. 2011 Nov 23.
18. Jain S., Ward M.M., O'Loughlin J., Boeck M., Wiener N., Chuang E., Cigler T. Moore A., Donovan D., Lam C., Cobham M.V., Schneider S., Christos P., Baergen R.N., Swistel A., Lane M.E., Mittal V., Rafii S., Vahdat L.T. Incremental increase in VEGFR1(+) hematopoietic progenitor cells and VEGFR2(+) endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients. Breast Cancer Res Treat. 2011 Dec 9.
19. Ramaswamy B., Fiskus W., Cohen B,. Pellegrino C. Hershman D.L., Chuang E. Luu T., Somlo G., Goetz M., Swaby R., Shapiro C.L., Stearns V., Christos P., Espinoza-Delgado I., Bhalla K., Sparano J.A.. Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo. Breast Cancer Res Treat. 2011 Dec 27.
20. Chuang E., Christos P., Flam A., McCarville K., Forst M., Shin S., Vahdat L., Swistel A., Osborne M., Moore A., Mazumdar M., Klein P. Breast cancer subtypes in Asian-Americans differ according to Asian ethnic group. J Immigr Minor Health. 2012 Jan 28.
21. Jain S., Ward M.M. Chuang E., Cigler T. Moore A., Donovan D., Lam C., Cobham M.V., Schneider S., Christos P., Swistel A., Lane M.E., Mittal V., Vahdat L.T. Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse. In press, Annals of Oncology.
Honors and Awards
Dr. Chuang was the recipient of a Clinical Investigator Award from the National Cancer Institute and a Junior Faculty Scholar Award from the American Society for Hematology.
- Breast Oncology
- Medical Oncology
- Breast Cancer
Contact and Practices
- Internal Medicine
- Medical Oncology
- M.D., University of Chicago Pritzker School of Medicine, 1989